Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Madalina Cercel"'
Autor:
Onno Kranenburg, Hergen Spits, Julien Villaudy, Madalina Cercel, Miriam Koopman, Cornelis J A Punt, Jamila Laoukili, Andre Verheem, Inne H M Borel Rinkes, Emre Küçükköse, Balthasar A Heesters, Susan van Hal, Sylvia F Boj, Jeanine M L Roodhart
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background The immunogenic nature of metastatic colorectal cancer (CRC) with high microsatellite instability (MSI-H) underlies their responsiveness to immune checkpoint blockade (ICB). However, resistance to ICB is commonly observed, and is associate
Externí odkaz:
https://doaj.org/article/bfcad88f61be41c09cf923011ef6cf7d
Autor:
Els Verdegaal, Hergen Spits, Remko Schotte, Martijn Kedde, Gemma Moiset, Hans Van Eenennaam, Pauline van Helden, Sjoerd van der Burg, Julien Villaudy, Wouter Pos, Daniel Go, Christien Fatmawati, Etsuko Yasuda, Madalina Cercel, Esmay Frankin, Susan van Hal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/db80a70a00dd4578b39f1f849964e0ec
Autor:
Julien Villaudy, Hergen Spits, S. E. van Hal-van Veen, Yvonne Claassen, Etsuko Yasuda, Lina Bartels, Madalina Cercel, Marijn A. Gillissen, Koen Wagner, Christien Fatmawati, Sophie E. Levie, Arjen Q. Bakker, Mette D. Hazenberg, Martijn Kedde, P. van Helden, Remko Schotte, G. de Jong, D. van de Berg, S.H. van der Burg, Els M. E. Verdegaal
Publikováno v:
Cancer immunology, immunotherapy, 70(6), 1569-1581. Springer Science and Business Media Deutschland GmbH
Cancer Immunology, Immunotherapy. SPRINGER
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy. SPRINGER
Cancer Immunology, Immunotherapy
Targeted cancer therapy with monoclonal antibodies has proven successful for different cancer types but is limited by the availability of suitable antibody targets. CD43s, a unique sialylated form of CD43 expressed by hematologic malignancies, is a r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dfe427f863db65bb706514800570b75
https://pure.amc.nl/en/publications/melanoma-cells-can-be-eliminated-by-sialylated-cd43--cd3-bispecific-t-cell-engager-formats-in-vitro-and-in-vivo(9f57d06a-6d38-4f3b-81cd-b7210005d696).html
https://pure.amc.nl/en/publications/melanoma-cells-can-be-eliminated-by-sialylated-cd43--cd3-bispecific-t-cell-engager-formats-in-vitro-and-in-vivo(9f57d06a-6d38-4f3b-81cd-b7210005d696).html
Autor:
Susan van Hal, Pauline M. van Helden, Els M. E. Verdegaal, Daniel Go, Martijn Kedde, Madalina Cercel, Hans van Eenennaam, Esmay Frankin, Etsuko Yasuda, Hergen Spits, Christien Fatmawati, Julien Villaudy, Sjoerd H. van der Burg, Wouter Pos, Gemma Moiset, Remko Schotte
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Adaptive immunity to cancer cells forms a crucial part of cancer immunotherapy. Recently, the importance of tumor B-cell signatures were shown to correlate with melanoma survival. We investigated whether tumor-targeting antibodies could be
Autor:
Anikó Szabó, Sjeng Horbach, Remko Schotte, Susan E. van Hal-van Veen, Madalina Cercel, Hans van Eenennaam, Anita W. Rijneveld, Dorien van de Berg, Mette D. Hazenberg, Wouter Pos, Yvonne Claassen, Etsuko Yasuda, Hergen Spits, Piet Gros, Christien Fatmawati, Julien Villaudy, Esmay Frankin, Greta de Jong, Sophie E. Levie, Daniel M Go, Martijn Kedde, Viviana Neviani
Publikováno v:
Blood. 136:41-42
Despite recent advances in treatment of B-acute lymphoblastic leukemia (B-ALL) there is still a need for novel targeted therapies. The tetraspanin CD9 is expressed in 60-80% of B-ALL and correlates with adverse prognosis. Recently, the mouse CD9 anti
Autor:
Mette D. Hazenberg, Hergen Spits, Marijn A. Gillissen, Veronika Kattler, Susan E. van Hal-van Veen, Greta de Jong, Lina Bartels, Madalina Cercel, Gemma Moiset, Etsuko Yasuda, Christien Fatmawati, Julien Villaudy, Camille Bru, Koen Wagner, Arjen Q. Bakker, Pauline M. van Helden
Publikováno v:
Cancer research, 79(13), 3372-3382. American Association for Cancer Research Inc.
Acute myeloid leukemia (AML) is a high-risk disease with a poor prognosis, particularly in elderly patients. Because current AML treatment relies primarily on untargeted therapies with severe side effects that limit patient eligibility, identificatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddcdf2e9a4e621407745ac10fc9da889
https://pure.amc.nl/en/publications/a-chemoenzymatically-linked-bispecific-antibody-retargets-t-cells-to-a-sialylated-epitope-on-cd43-in-acute-myeloid-leukemia(5c4bebcc-4bdd-42cd-8aab-ae402751ab57).html
https://pure.amc.nl/en/publications/a-chemoenzymatically-linked-bispecific-antibody-retargets-t-cells-to-a-sialylated-epitope-on-cd43-in-acute-myeloid-leukemia(5c4bebcc-4bdd-42cd-8aab-ae402751ab57).html
Autor:
Remko Schotte, Anita W. Rijneveld, H. van Eenennaam, Anikó Szabó, Sophie E. Levie, Etsuko Yasuda, Julien Villaudy, Hergen Spits, Martijn Kedde, S.H. van der Burg, Madalina Cercel, Viviana Neviani, Sjeng Horbach, Christien Fatmawati, G. de Jong, Wouter Pos, Piet Gros, P. van Helden, Mette D. Hazenberg, Els M. E. Verdegaal
Publikováno v:
Annals of Oncology. 31:S493
Autor:
Els M. E. Verdegaal, Remko Schotte, H. van Eenennaam, Madalina Cercel, Gemma Moiset, S.H. van der Burg, Wouter Pos, Christien Fatmawati, S. E. van Hal-van Veen, Etsuko Yasuda, Esmay Frankin, P. van Helden, Julien Villaudy, D. Go, Hergen Spits, Martijn Kedde, Koen Wagner
Publikováno v:
Annals of Oncology. 31:S492
Autor:
Mette D. Hazenberg, Hergen Spits, Anikó Szabó, Greta de Jong, Remko Schotte, Madalina Cercel, Hans van Eenennaam, Martijn Kedde, Etsuko Yasuda, Pauline M. van Helden, Els M. E. Verdegaal, Sjoerd H. van der Burg, Wouter Pos, Sophie E. Levie, Esmay Frankin, Julien Villaudy, Daniel Go, Susan van Hal, Anita van Rijneveld
Publikováno v:
Cancer Research. 80:531-531
Introduction Despite rapid advances in immunotherapeutic options for precursor B-acute lymphoblastic leukemia (BCP-ALL), outcomes remain poor especially for adult ALL and relapsed pediatric ALL. With conventional chemotherapy remission percentages in
Autor:
Greta de Jong, Els M. E. Verdegaal, Lina Bartels, Koen Wagner, Christien Fatmawati, Susan E. van Hal-van Veen, Etsuko Yasuda, Mette D. Hazenberg, Arjen Q. Bakker, Dorien van de Berg, Hergen Spits, Martijn Kedde, Marijn A. Gillissen, Madalina Cercel, Remko Schotte, Pauline M. van Helden, Julien Villaudy, Yvonne Claassen, Sophie E. Levie
Publikováno v:
Cancer Research. 80:542-542
Introduction CD43s, a unique sialylated form of CD43 expressed by myeloid malignancies, is a novel target and AT1413, an antibody targeting CD43s was shown to have therapeutic potential against acute myeloid leukemia (AML) and myelodysplastic syndrom